^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
EMB-02
i
Other names: EMB-02, EMB02, EMB 02
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
EpimAb Biotherap
Drug class:
PD1 inhibitor, LAG-3 inhibitor
Related drugs:
8ms
First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors. (PubMed, Br J Cancer)
EMB-02 demonstrated a favorable safety profile and early efficacy signals in multiple solid tumors, warranting further development. (NCT04618393).
P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
|
PD-L1 expression
|
EMB-02
9ms
Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB-02) in Patients With Advanced Solid Tumors. (PubMed, CPT Pharmacometrics Syst Pharmacol)
Based on these findings, two dosing regimens have been selected for further clinical development. Trial Registration: ClinicalTrials.gov identifier: NCT04618393.
PK/PD data • Journal
|
LAG3 (Lymphocyte Activating 3)
|
EMB-02
over1year
A Study of EMB-02 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=47, Terminated, Shanghai EpimAb Biotherapeutics Co., Ltd. | Trial completion date: Dec 2025 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Jul 2023; Company's resource optimization and product's development change
Trial completion date • Trial termination • Trial primary completion date
|
EMB-02
over2years
Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors (ESMO 2023)
Conclusions EMB-02 has demonstrated a tolerable safety profile and encouraging anti-tumor activity during the dose escalation phase, warranting further development. Expansion cohorts in select advanced solid tumours are ongoing.
Clinical • P1 data • Metastases
|
LAG3 (Lymphocyte Activating 3)
|
LAG3 expression
|
EMB-02
Share via
